Every day thousands of people in the USA alone are beginning to fight cancer. In 2016, more than 4,600 individuals in the U.S. were diagnosed with cancer daily. The first step to fighting cancer is identifying its presence early, which can be a difficult and frustrating process.

The IvyGene test is a blood test able to detect and measure DNA methylation patterns that are consistent with actual cancer presence. A highly accurate and sensitive cancer test, the IvyGene test is a non-invasive tool to aid physicians in identifying cancer presence.

According to studies performed by the National Cancer Institute and the American Cancer Society, individuals who identified 25 different types of cancer earlier had a greater chance of survival.

In combination with diagnostic tests, the IvyGene cancer test is another step towards winning the battle with cancer.

The IvyGenecode test is a blood test that measures the methylation status of cell-free DNA at target sites that have been demonstrated to be hypermethylated when certain cancers are present.

Test results are reported as a quantitative IvyGene Score, which indicates the methylation status of the target sites. The IvyGene Score is calculated as a composite average of cell-free DNA that is methylated at the target sites as a fraction of the total cell-free DNA present.

An IvyGene Score of 1-19 is considered normal. An IvyGene Score of 20 or greater is considered elevated.

The IvyGene test can provide additional insight and is supplementary to other standard of care diagnostics. It provides a non-invasive option to aid in the following:

• Confirm specific cancer presence
• Supplement other tests
• Follow-up to other diagnostics and screening tests. Such as: abnormal imaging and BRCA1 and BRCA2.
• Monitor for recurrence